Minister of Commerce Wang Wentao held intensive meetings with several multinational pharmaceutical company leaders, fully engaging in the "Healthy China" initiative, which presents new opportunities.

MetaMuskRat · 2026-03-22T22:44:53+00:00

Commerce Minister Wang Wentao held talks with executives from multiple multinational pharmaceutical companies, emphasizing the development opportunities brought by China's "15th Five-Year Plan," particularly in biopharmaceuticals and health priority strategies. Company leaders expressed strong confidence and willingness to increase investment in China to support "Healthy China" initiatives.

MetaMuskRat

2026-03-22 22:44:53

Abstract generation in progress

Securities Times Reporter Qin Yanling

According to the Ministry of Commerce, from March 20 to March 21, Minister Wang Wentao held intensive meetings with several senior executives of multinational pharmaceutical companies. He introduced the opportunities in China outlined in the “14th Five-Year Plan” and provided more stable development expectations for foreign investment.

On March 21, Wang Wentao met with Wu Sipao, President and CEO of the Pharmaceutical Research and Manufacturers of America (PhRMA), as well as leaders from Novartis, AstraZeneca, Roche Group, Boehringer Ingelheim, and Otsuka Pharmaceutical. He pointed out that the “14th Five-Year Plan” explicitly emphasizes implementing a health-first development strategy, listing biopharmaceuticals as a new pillar industry, strengthening intellectual property protection, increasing policy transparency, and improving regulatory efficiency. These measures create new opportunities for multinational pharmaceutical companies to participate comprehensively in the construction of a “Healthy China.”

Representatives from the associations and multinational pharmaceutical companies attending the meeting stated that China holds a significant position in the global pharmaceutical market, has integrated into the global biopharmaceutical innovation ecosystem, and remains optimistic about the future development of China’s pharmaceutical industry. They expressed willingness to increase investment, introduce more cutting-edge international products and technologies into China, and contribute to the “Healthy China” initiative.

On March 20, Wang Wentao also met with David Ricks, Chairman and CEO of Eli Lilly. Ricks said that China’s “14th Five-Year Plan” presents opportunities for multinational companies. Eli Lilly is optimistic about its development prospects in China and plans to increase its investment by $3 billion over the next decade to support the construction of a “Healthy China.”

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes